| Global burden of cardiovascular diseases and risks, 1990-2022 GA Mensah, V Fuster, CJL Murray, GA Roth, ... Journal of the American College of Cardiology 82 (25), 2350-2473, 2023 | 101 | 2023 |
| Amyand’s hernia: an up-to-date review of the literature D Patoulias, M Kalogirou, I Patoulias Acta medica 60 (3), 131-134, 2018 | 76 | 2018 |
| Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors D Patoulias, C Papadopoulos, K Stavropoulos, I Zografou, M Doumas, ... The Journal of Clinical Hypertension 22 (4), 562-571, 2020 | 55 | 2020 |
| Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities D Patoulias, A Katsimardou, K Stavropoulos, K Imprialos, MS Kalogirou, ... Current hypertension reports 22, 1-13, 2020 | 47 | 2020 |
| COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute? M Doumas, D Patoulias, A Katsimardou, K Stavropoulos, K Imprialos, ... Journal of human hypertension 34 (11), 764-767, 2020 | 43 | 2020 |
| Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the … AE Schumacher, HH Kyu, A Aali, C Abbafati, J Abbas, ... The Lancet 403 (10440), 1989-2056, 2024 | 40 | 2024 |
| Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 JD Steinmetz, KM Seeher, N Schiess, E Nichols, B Cao, C Servili, ... The Lancet Neurology 23 (4), 344-381, 2024 | 39 | 2024 |
| Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the … M Naghavi, KL Ong, A Aali, HS Ababneh, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2100-2132, 2024 | 34 | 2024 |
| Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis P Dimitrios, D Michael, K Vasilios, S Konstantinos, I Konstantinos, ... Current Diabetes Reviews 16 (4), 313-326, 2020 | 33 | 2020 |
| Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials D Patoulias, M Doumas, C Papadopoulos, A Karagiannis Clinical Rheumatology 40 (11), 4671-4674, 2021 | 32 | 2021 |
| Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials DI Patoulias, A Boulmpou, E Teperikidis, A Katsimardou, F Siskos, ... World Journal of Cardiology 13 (10), 585, 2021 | 30 | 2021 |
| Efficacy and safety of renal denervation for the management of arterial hypertension: a systematic review and meta‐analysis of randomized, sham‐controlled, catheter‐based trials K Stavropoulos, D Patoulias, K Imprialos, M Doumas, A Katsimardou, ... The Journal of Clinical Hypertension 22 (4), 572-584, 2020 | 29 | 2020 |
| Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies D Patoulias, M Doumas Endocrinology and Metabolism 36 (4), 904-908, 2021 | 27 | 2021 |
| Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review C Papadopoulos, D Patoulias, E Teperikidis, D Mouselimis, A Tsarouchas, ... SN Comprehensive Clinical Medicine 2, 1419-1429, 2020 | 27 | 2020 |
| Inflammatory markers in cardiovascular disease; lessons learned and future perspectives D Patoulias, K Stavropoulos, K Imprialos, V Athyros, H Grassos, ... Current vascular pharmacology 19 (3), 323-342, 2021 | 25 | 2021 |
| Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice D Patoulias, A Manafis, C Mitas, K Avranas, G Lales, I Zografou, ... Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current …, 2018 | 25 | 2018 |
| Reduction of vascular inflammation, LDL-C, or both for the protection from cardiovascular events? A Reklou, M Doumas, K Imprialos, K Stavropoulos, D Patoulias, ... The open cardiovascular medicine journal 12, 29, 2018 | 25 | 2018 |
| Hydrocele in pediatric population I Patoulias, E Koutsogiannis, I Panopoulos, P Michou, T Feidantsis, ... Acta Medica 63 (2), 57-62, 2020 | 20 | 2020 |
| SGLT-2 inhibitors in type 1 diabetes mellitus: a comprehensive review of the literature D Patoulias, K Imprialos, K Stavropoulos, V Athyros, M Doumas Current Clinical Pharmacology 13 (4), 261-272, 2018 | 18 | 2018 |
| Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) and its soluble in the plasma form (sTREM-1) as a diagnostic biomarker in neonatal sepsis D Patoulias, MS Kalogirou, I Patoulias Folia Medica Cracoviensia 58 (2), 2018 | 18 | 2018 |
